Please ensure Javascript is enabled for purposes of website accessibility

Inovio Pharmaceuticals Accelerates Timeline for Its Coronavirus Vaccine, Shares Jump 70%

By Brian Orelli, PhD - Updated Jun 26, 2020 at 11:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech wants to start testing its candidate vaccine against SARS-CoV-2 in April.

Inovio Pharmaceuticals (INO -3.48%) is making progress in its efforts to develop a vaccine for SARS-CoV-2, the coronavirus that causes COVID-19. Shares of the biotech company closed up 70% on Tuesday on word that it could start a clinical trial next month.

Rather than using inactivated viruses like traditional vaccines, Inovio's platform uses DNA to express a protein from the virus in patients' cells. The immune system recognizes the protein as foreign and develops antibodies to it, in theory providing immunity if the patient is infected with the virus. The simplicity of that system allowed Inovio to design its vaccine, INO-4800, in three hours after the company gained access to the sequence of the novel coronavirus.

At the time, Inovio said it planed to start clinical testing as early as this summer. The increased spread of the disease has accelerated that timeline.

People on the sidewalk wearing masks

Image source: Getty Images.

The biotech has already started pre-clinical testing which will continue this month while it finalizes the clinical trial design. Inovio plans to manufacture 3,000 doses of its vaccine candidate this month to be used in clinical trials.

Inovio plans to start a clinical trial in 30 healthy volunteers in the U.S. next month with the thought to expand to people in China and South Korea shortly thereafter. Data from the studies would be available in the fall.

By the end of the year, Inovio is hoping to have 1 million doses of INO-4800 available for additional clinical trials or emergency use depending on what regulators want at that point.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.94 (-3.48%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.